plasminogen activator

Cloning of Human Tissue-type Plasminogen Activator ( t-PA) cDNA, Construction of Its Eukaryotic Expression Vector and Its Expression in in Vivo Small-diameter Vascular Anastomotic Sites

t-PA基因克隆、真核表达载体的构建及其在在体小血管吻合口中的表达肌动蛋白与真核生物的进化真核微生物的类金属硫蛋白

Establishment and Standardization of the National Reference Standard of Recombinant Human Tissue Plasminogen Activator

首批重组人组织纤溶酶原激活剂国家标准品的研制

Objective: To identify of urokinase-type plasminogen activator ( UPA ) expression in patients with epithelial ovarian carcinoma.

目的: 探讨尿激酶型纤溶酶原激活因子 ( UPA ) 的蛋白表达与上皮性卵巢癌生物学行为的关系.

Inhibition of Invasiveness of Human Breast Cancer Cells by siRNA Against Urokinase-type Plasminogen Activator

针对uPA的siRNA对人乳腺癌细胞侵袭的抑制作用

Transient expression of tissue-type plasminogen activator in mammary carcinoma cell line MCF-7

MCF-7细胞中组织型纤溶酶原激活剂乳腺特异性表达载体的瞬时表达

Isolation of Two Types of Plasminogen Activator from Human Fetal Lung Cell Conditioned Medium

人胎肺细胞的条件化培养液中两种类型纤溶酶原活化物的分离

Research advances in tissue-type plasminogen activator mediated ocular dominance column plasticity

tPA参与眼优势柱可塑性的研究进展

In this process, urokinase-type plasminogen activator ( uPA ) and P-selectin play a very important role.

在此过程中, 尿激酶型纤溶酶原激活物(urokinase -type plasminogenactivator,uPA ) 和P - 选择素起着十分重要的作用.

A luminescence solid phase assay for tissue type plasminogen activator ( t-PA) was developed.

本文建立了组织型纤溶酶原激活剂（t-PA）活力的发光固相测定方法。

The regulatory effect of tissue plasminogen activator involved in central nervous insult

组织型纤溶酶原激活物在中枢神经损伤中的调节作用

Analysis of Recombinant Human Tissue Plasminogen Activator and Its Mutants

重组人组织纤维蛋白溶酶原激活剂及突变体的分析

The Initial Research about the Effect of Tissue Plasminogen Activator on Neural Repair

组织纤溶酶原激活物对神经修复影响的初步探讨

Nursing care of patients with acute myocardial infarction treated with recombinant human tissue plasminogen activator

重组人组织纤溶酶原激活剂治疗急性心肌梗死病人的护理

Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery

前房内注射组织纤溶酶原激活剂预防先天性白内障术后严重的纤维渗出

One step Purification of Tissue type Plasminogen Activator Derived from Expression by Milk Gland of Transgenic Goat Using Affinity Chromatography

应用一步亲和层析法纯化转基因山羊乳腺定位表达的组织型纤维蛋白溶酶原激活剂

We detected plasma tissue plasminogen activator ( t-PA) and plasminogen activator Inhibitor ( PAI) activity in 52 patients with acute leukemia ( AL) by a chromogenic substrate method.

应用发色底物比色分析法，对42例正常人和52例急性白血病（AL）病人血浆组织纤溶酶原激活剂（t-PA）、组织纤溶酶原激活剂抑制剂（PAI）活性进行了检测。

Study on tissue plasminogen activator change in recurrence of stroke patients The blindness was secondary to embolic infarction of both occipital lobes developing as a sequela of IE.

血纤溶活性变化对缺血性脑梗死复发的影响眼盲次发于两侧脑枕叶血栓性梗塞，为感染性心内膜炎的并发症。

Construction of a Human Tissue-type Plasminogen Activator Tissue Specific Expression Vector and Establishment of Its Transgenic Mice

tPA乳腺组织特异性表达载体构建及转基因小鼠建立

Special Types of Hemorrhagic Transformation in Patients Treated by Intravenous Recombinant Tissue Plasminogen Activator

急性缺血性脑卒中rt-PA静脉溶栓后出血性转化的特殊类型

Clinical observation of treating intraocular hemorrhage with tissue plasminogen activator

t-PA治疗眼内出血的初步临床观察

Establishment of a Sandwich ELISA for Quantitative Measurement of Tissue-type Plasminogen Activator

定量检测组织型纤溶酶原激活剂夹心ELISA方法的建立

Establishment of Transgenic Goats for Human Tissue-type Plasminogen Activator with Sperm Mediated Gene Transfer Method

利用精子载体方法研制人组织型纤溶酶原激活剂突变体转基因羊乳腺生物反应器

Purification and Biochemical Properties of Tissue Plasminogen Activator from Porcine Heart

组织型纤溶酶原活化物的纯化及性质研究

A Clinical Study on Prehospital Versus In-hospital Intravenous Thrombolytic Therapy With Low Dose Recombinant Tissue-Type Plasminogen Activator in Acute Myocardial Infarction Patients

院前、院内小剂量重组组织型纤溶酶原激活剂静脉溶栓治疗急性心肌梗死的临床研究

The clinical research of Urokinase-type plasminogen activator receptor ( CD87) as a factor predicting worse prognosis in acute myeloid leukaemia patients

CD87用于急性髓细胞白血病预后判断的临床研究

Objective To investigate the relationship between the 4G/ 5G gene polymorphism of the plasminogen activator inhibitor 1 ( PAI 1) and myocardial and cerebrovascular infarctions.

目的研究我国汉族人纤溶酶原激活物抑制物1基因启动子区675位4G5G（单鸟嘌呤核苷酸插入缺失）基因多态性与心肌梗死和脑梗死的等位基因特异性的相关性。

The Studies of the Role of Tissue Plasminogen Activator in Brain Injury after Cerebral Ischemia

组织纤溶酶原激活物在脑缺血后神经损伤中的作用及其机制研究

PURPOSE : To establish a stable cell strain secreted recombinant tissue-type plasminogen activator ( rt-PA ).

目的: 建立稳定表达人组织型纤溶酶原激活剂 ( tissue -type plasminogenactivatort -PA ) 的细胞系.

Changes of Tissue-type Plasminogen Activator and Plasminogen Activator Inhibitor Activity in Plasma of Asphyxial Fetal Mice Embryo

窒息胎鼠血浆组织型纤溶酶原激活剂及其抑制物的变化

Objective To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using low dose recombinant tissue plasminogen activator ( r-TPA) and recombinant strepokinase ( r-SK) in patients with acute myocardial infarction ( AMI).

目的评价小剂量重组组织型纤溶酶原激活物（r-TPA）与国产重组链激酶（r-SK）治疗急性心肌梗死（AMI）的疗效，并比较二者的差异。